Cargando…
Antibody engineering to develop new antirheumatic therapies
There has been a therapeutic revolution in rheumatology over the past 15 years, characterised by a move away from oral immuno-suppressive drugs toward parenteral targeted biological therapies. The potency and relative safety of the newer agents has facilitated a more aggressive approach to treatment...
Autor principal: | |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2714093/ https://www.ncbi.nlm.nih.gov/pubmed/19490600 http://dx.doi.org/10.1186/ar2594 |
_version_ | 1782169634026291200 |
---|---|
author | Isaacs, John D |
author_facet | Isaacs, John D |
author_sort | Isaacs, John D |
collection | PubMed |
description | There has been a therapeutic revolution in rheumatology over the past 15 years, characterised by a move away from oral immuno-suppressive drugs toward parenteral targeted biological therapies. The potency and relative safety of the newer agents has facilitated a more aggressive approach to treatment, with many more patients achieving disease remission. There is even a prevailing sense that disease 'cure' may be a realistic goal in the future. These developments were underpinned by an earlier revolution in molecular biology and protein engineering as well as key advances in our understanding of rheumatoid arthritis pathogenesis. This review will focus on antibody engineering as the key driver behind our current and developing range of antirheumatic treatments. |
format | Text |
id | pubmed-2714093 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2009 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-27140932009-11-19 Antibody engineering to develop new antirheumatic therapies Isaacs, John D Arthritis Res Ther Review There has been a therapeutic revolution in rheumatology over the past 15 years, characterised by a move away from oral immuno-suppressive drugs toward parenteral targeted biological therapies. The potency and relative safety of the newer agents has facilitated a more aggressive approach to treatment, with many more patients achieving disease remission. There is even a prevailing sense that disease 'cure' may be a realistic goal in the future. These developments were underpinned by an earlier revolution in molecular biology and protein engineering as well as key advances in our understanding of rheumatoid arthritis pathogenesis. This review will focus on antibody engineering as the key driver behind our current and developing range of antirheumatic treatments. BioMed Central 2009 2009-05-19 /pmc/articles/PMC2714093/ /pubmed/19490600 http://dx.doi.org/10.1186/ar2594 Text en Copyright © 2009 BioMed Central Ltd |
spellingShingle | Review Isaacs, John D Antibody engineering to develop new antirheumatic therapies |
title | Antibody engineering to develop new antirheumatic therapies |
title_full | Antibody engineering to develop new antirheumatic therapies |
title_fullStr | Antibody engineering to develop new antirheumatic therapies |
title_full_unstemmed | Antibody engineering to develop new antirheumatic therapies |
title_short | Antibody engineering to develop new antirheumatic therapies |
title_sort | antibody engineering to develop new antirheumatic therapies |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2714093/ https://www.ncbi.nlm.nih.gov/pubmed/19490600 http://dx.doi.org/10.1186/ar2594 |
work_keys_str_mv | AT isaacsjohnd antibodyengineeringtodevelopnewantirheumatictherapies |